Abstract
We present two Delta (B.1.617.2) vaccine breakthrough individuals, a father and son living in separate households. The older, 63-year-old patient’s symptoms were severe enough to require hospitalization. Despite having a high titer of anti-spike IgG in his serum, his symptoms resolved within 24 hours following monoclonal antibody (bamlanivimab/etesevimab) therapy.
Keywords: B.1.617.2; COVID-19; Delta variant; SARS-CoV-2; bamlanivimab/etesevimab; breakthrough; monoclonal antibody therapy; variant of concern.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, B.1.617.2, delta variant, monoclonal antibody therapy, variant of concern, breakthrough, bamlanivimab/etesevimab, 【초록키워드】 Vaccine, therapy, Hospitalization, monoclonal antibody, variant, Delta, B.1.617.2, Symptom, delta variant, bamlanivimab, monoclonal antibody therapy, serum, anti-Spike IgG, etesevimab, Patient, 24 hours, Older, father and son, father, individuals, resolved, 24 hour, 【제목키워드】 Delta, monoclonal antibody therapy,
【저자키워드】 COVID-19, SARS-CoV-2, B.1.617.2, delta variant, monoclonal antibody therapy, variant of concern, breakthrough, bamlanivimab/etesevimab, 【초록키워드】 Vaccine, therapy, Hospitalization, monoclonal antibody, variant, Delta, B.1.617.2, Symptom, delta variant, bamlanivimab, monoclonal antibody therapy, serum, anti-Spike IgG, etesevimab, Patient, 24 hours, Older, father and son, father, individuals, resolved, 24 hour, 【제목키워드】 Delta, monoclonal antibody therapy,
{{{ 추상적인 }}}
우리는 두 명의 델타(B.1.617.2) 백신 돌파구 개인, 아버지와 아들이 별거 중인 가정을 소개합니다. 63세의 고령 환자의 증상은 입원이 필요할 정도로 심각했다. 그의 혈청에 높은 역가의 항스파이크 IgG가 있음에도 불구하고 그의 증상은 단일클론항체(밤라니비맙/에테세비맙) 치료 후 24시간 이내에 해결되었습니다.
{{ 키워드: }} B.1.617.2; 코로나바이러스감염증-19 : 코로나19; 델타 변형; 사스 코로나바이러스 2; 밤라니비맙/에테세비맙; 돌파구; 단일클론항체 요법; 우려의 변형.